Table 3. Summary of Test Performance for Surveillance PET-CT and PET.
| Author, Year | Participants n |
TP | FN | TN | FP | Sensitivity 95% CI | Specificity 95% CI | PPV, 95% CI NPV, 95% CI |
LR+, 95% CI LR-, 95% CI |
Time of PET / PET-CT Scan |
|---|---|---|---|---|---|---|---|---|---|---|
| PET-CT | ||||||||||
|
| ||||||||||
| Lymphoma | ||||||||||
|
| ||||||||||
| Crocchiolo, 2009(22) |
27 | 6 | 0 | 15 | 6 | 100 54-100 |
71 48-88 |
0.50, 0.25-0.75; 1, 0.80-1.00 |
3.50, 1.78-6.88; not calculable; |
-1st year every 4 mo -2nd/3rd year every 6 mo -Yearly thereafter |
| El-Galaly, 2011(23) |
52 | 1 | 0 | 47 | 4 | 100 3-100* |
92 80-97* |
0.20, 0.04-0.62; 1.00, 0.92-1.00 | 12.8, 4.98-32.7; not calculable |
Half-yearly scan for the first 2 yr after treatment; mean 2.6 scans per patient during the first 2 yr. |
| Lee, 2010(21) |
192 | 9 | 3 | 162 | 18 | 75 43-93 |
90 84-94 |
0.33, 0.19-0.52; 0.98, 0.95-0.99 | 7.50, 4.34-13.0; 0.28, 0.10-0.74 |
Variable timing and frequency |
| Rhodes, 2006(24) |
41 | 6 | 0 | 15 | 20 | 100 54-100 |
43 27-60 |
0.23, 0.11-0.42; 1, 0.80-1.00 | 1.75, 1.31-2.33; not calculable |
Variable, within 30 mos after negative post-treatment PET-CT (Per-patient calculation, equivocal scans considered positive) |
| 6 | 0 | 28 | 7 | 100 54-100 |
80 63-91 |
0.46, 0.23-0.71; 1.00, 0.88-1.00 | 5.0, 2.58-9.70; not calculable |
(Per-patient calculation, equivocal scans considered negative) | ||
| 247 scans | 18 | 1 | 154 | 74 | 95 72-100 |
68 61-73 |
0.20, 0.13-0.29; 0.99, 0.96-1.00 | 2.92, 2.35-3.62; 0.08, 0.01-0.53 | (Per-scan calculation, equivocal scans considered positive) | |
| 18 | 1 | 212 | 16 | 95 72-100 |
93 89-96 |
0.53, 0.37-0.69; 1, 0.97-1.00 | 13.5, 8.3-21.9; 0.06, 0.01-0.38 | (Per-scan calculation, equivocal scans considered negative) | ||
|
| ||||||||||
| Head and Neck Cancer | ||||||||||
|
| ||||||||||
| Abgral, 2009(25) |
91 | 30 | 0 | 52 | 9 | 100 88-100 |
85 73-93 |
0.77, 0.62-0.87; 1, 0.93-1.00 | 6.78; 3.71-12.4 | One scan at mean 11.6 mo Follow-up in 6 mo |
|
| ||||||||||
| PET | ||||||||||
|
| ||||||||||
| Lymphoma | ||||||||||
|
| ||||||||||
| Hosein 2011(27) |
34 | nd | nd | nd | nd | nd | Nd | nd | nd | Every 6 mo for 3 yr |
| 162 scans | 83 36-97 |
64 56-72 |
||||||||
|
| ||||||||||
| Zinzani 2009(26) |
421 | 41 | 5 | 375 | 0 | 89 76-96 |
100 99-100** |
1.00, 0.91-1.00; 0.99, 0.97-0.99 | not calculable; 0.11, 0.05-0.25 | Every 6 mo first 2 years, then annually |
| 46 | 0 | 358 | 17 | 100 92-100 |
95 93-97** |
0.73, 0.61-0.82; 1.00, 0.99-1.00 | 22.1, 13.9-35.1; not calculable |
|||
|
| ||||||||||
| Head and Neck Cancer | ||||||||||
|
| ||||||||||
| Lowe, 2000(29) |
30 | 16 | 0 | 13 | 1 | 100 79-100 |
93 64-100 |
0.94, 0.73-0.99; 1, 0.77-1.00 | 14, 2.12-92.6; not calculable |
Once at 10 mo |
|
| ||||||||||
| Perie, 2007(30) |
43 | 3 | 1 | 36 | 3 | 75 22-99 |
92 78-98 |
0.50, 0.19-0.81; 0.97, 0.86-1.00 | 9.75, 2.86-33.2; 0.27, 0.05-1.48 |
Once at 1 yr |
|
| ||||||||||
| Salaun, 2007(31) |
30 | 8 | 0 | 21 | 1 | 100 63-100 |
95 75-100 |
0.89, 0.57-0.98; 1.00, 0.85-1.00 |
22.0, 3.24-149; not calculable |
Once at mean of 21 (+/-13.7) mo |
|
| ||||||||||
| Colorectal | ||||||||||
|
| ||||||||||
| Selvaggi, 2002(28) |
31 | 4 | 0 | 26 | 1 | 100 40-100 |
96 79-100 |
0.80, 0.38, 0.96; 1, 0.87-1.00 | 27.0, 3.95-184; not calculable |
At 2 yr, after negative body CT and MRI at 1, 2 yr |
|
| ||||||||||
| Sobhani, 2008(20) |
65 (ITT) | nd | nd | nd | nd | 91 | 92 | nd | nd | At 9 mo and 15 mo |
nd = No data; N/A = Not applicable
ITT = intention to treat
PPV = positive predicted value, NPV = negative predicted value
LR+ = positive likelihood ratio, LR- = negative likelihood ratio
*
result of the first scan 6 months after treatment;
**
2×2 table not provided in study. To estimate test accuracy, we performed two analyses--treating inconclusive tests as negative in the first row and as positive in the second row.